Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1955 1
1959 1
1960 1
1963 8
1964 3
1965 1
1966 2
1967 1
1968 4
1969 1
1970 5
1971 3
1974 1
1975 1
1976 3
1977 4
1978 2
1979 4
1981 2
1983 3
1984 6
1985 2
1986 6
1987 3
1988 2
1989 2
1992 1
1993 4
1994 2
1995 8
1996 2
1997 6
1998 4
1999 1
2000 3
2001 1
2002 2
2003 7
2004 7
2005 5
2006 6
2007 3
2008 7
2009 8
2010 9
2011 11
2012 4
2013 7
2014 9
2015 5
2016 4
2017 5
2018 6
2019 6
2020 14
2021 15
2022 21
2023 11
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Results by year

Filters applied: . Clear all
Page 1
Small molecule approaches to targeting RNA.
Kovachka S, Panosetti M, Grimaldi B, Azoulay S, Di Giorgio A, Duca M. Kovachka S, et al. Among authors: duca m. Nat Rev Chem. 2024 Feb;8(2):120-135. doi: 10.1038/s41570-023-00569-9. Epub 2024 Jan 26. Nat Rev Chem. 2024. PMID: 38278932 Review.
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.
Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS. Rottey S, et al. Among authors: duca m. Clin Cancer Res. 2022 Jan 1;28(1):95-105. doi: 10.1158/1078-0432.CCR-21-1181. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615718 Free PMC article. Clinical Trial.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: duca m. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
The Chemical Biology-Medicinal Chemistry Continuum: EFMC's Vision.
Duca M, Gillingham D, Olsen CA, Sbardella G, Skaanderup PR, van der Stelt M, Vauzeilles B, Vázquez O, Auberson YP. Duca M, et al. Chembiochem. 2021 Oct 1;22(19):2823-2825. doi: 10.1002/cbic.202100319. Epub 2021 Aug 4. Chembiochem. 2021. PMID: 34347337
EFMC: Trends in Medicinal Chemistry and Chemical Biology.
Auberson YP, Arimondo PB, Duca M, Essig S, Grether U, Rufer AC, Sbardella G, Schopfer U, Torrens A, van der Stelt M, Vauzeilles B, Vázquez O, Zhang AX. Auberson YP, et al. Among authors: duca m. Chembiochem. 2023 Apr 3;24(7):e202200690. doi: 10.1002/cbic.202200690. Epub 2023 Feb 28. Chembiochem. 2023. PMID: 36704975 Review.
Stereoselective Protection-Free Modification of 3-Keto-saccharides.
Marinus N, Tahiri N, Duca M, Mouthaan LMCM, Bianca S, van den Noort M, Poolman B, Witte MD, Minnaard AJ. Marinus N, et al. Among authors: duca m. Org Lett. 2020 Jul 17;22(14):5622-5626. doi: 10.1021/acs.orglett.0c01986. Epub 2020 Jul 7. Org Lett. 2020. PMID: 32635733 Free PMC article.
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.
Rivoltini L, Camisaschi C, Fucà G, Paolini B, Vergani B, Beretta V, Damian S, Duca M, Cresta S, Magni M, Leone BE, Castelli C, de Braud F, De Santis F, Di Nicola M. Rivoltini L, et al. Among authors: duca m. Sci Rep. 2024 Feb 9;14(1):3379. doi: 10.1038/s41598-024-54041-9. Sci Rep. 2024. PMID: 38336861 Free PMC article. Clinical Trial.
Nitrogen cycle electrocatalysis.
Rosca V, Duca M, de Groot MT, Koper MT. Rosca V, et al. Among authors: duca m. Chem Rev. 2009 Jun;109(6):2209-44. doi: 10.1021/cr8003696. Chem Rev. 2009. PMID: 19438198 Review. No abstract available.
275 results